Improving antiviral medication for COVID-19 gives more patients access to treatments

Researchers from the University of Alberta are using the CLS to improve Paxlovid so it can be used by people who are immunocompromised or have other chronic conditions. The COVID antiviral uses a second drug as a metabolic booster to keep the active drug in the blood stream longer. However, this additive can interact with other medications. The U of A team modified a specific area of the molecule in the active drug so it stays in the system - meaning an additional “booster” drug is not necessary. The team is now working to expand what they learned to design drugs to help fight other viruses.
To read the full story online, go to: www.lightsource.ca/public/new...